Corvus Pharmaceuticals, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Corvus Pharmaceuticals, Inc. (CRVS) on May 1, 2024. The filing addresses an amendment to an existing At-the-Market (ATM) Offering Program previously established with Jefferies LLC.
Key Financial Metrics
The filing does not report revenue, profit, cash flow, margins, or debt levels. The primary financial data disclosed relates to the ATM Offering Program:
- Original Aggregate Offering Price: $90.0 million (established March 28, 2023).
- Amended Aggregate Offering Price: $8.2 million (effective May 1, 2024).
- Total Shares Sold to Date: Approximately $8.1 million.
- Remaining Availability: Approximately $100,000.
Material Changes
The material change reported is the reduction of the aggregate offering price under the 2023 Sales Agreement from $90.0 million to $8.2 million. This amendment reflects that the Company has already sold approximately $8.1 million of shares under the program, leaving minimal remaining capacity.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard legal disclaimers regarding the offer of securities. The document notes that the description of the Amendment is qualified by reference to the full text of Exhibit 1.1.
Investor Verification Checklist
- Verify the exact number of shares sold to date to confirm the $8.1 million figure.
- Review Exhibit 1.1 (Amendment No. 1 to Sales Agreement) for specific terms regarding the termination or expiration of the program once the remaining $100,000 is utilized.
- Confirm if the Company intends to establish a new ATM program or alternative financing mechanisms given the near-exhaustion of the current facility.